SHENZHEN DYMIND BIOTECHNOLOGY CO.,LTD. - Medical Device Manufacturer in Indonesia
SHENZHEN DYMIND BIOTECHNOLOGY CO.,LTD. from China is a medical device manufacturer with 5 registered products in the Indonesia BPOM database through Pure Global AI's free platform. The company produces 5 unique product types across 1 product class.
This page provides comprehensive manufacturer intelligence including complete product portfolio, risk class distribution, and product class analysis. Pure Global AI offers free access to 67,600+ Indonesia medical device registrations, helping global MedTech companies identify manufacturers, analyze portfolios, and discover partnership opportunities efficiently.
Free Manufacturer Profile
Powered by Pure Global AI
5 Products
1 Classes
๐ฎ๐ฉ
SHENZHEN DYMIND BIOTECHNOLOGY CO.,LTD.
China
5
Total Products
5
Product Names
1
Product Classes
1
Risk Classes
Risk Classification Breakdown
Distribution of products across risk classes
Kelas Resiko : B
5 products100.0%
Product Class Portfolio
Products organized by product class
Kelas : 2
5 Products
DYMIND Hematology Analyzer Lyse LYC-2
Kelas Resiko : B
Mar 10, 2023
DYMIND Hematology Analyzer Diluent DIL-C
Kelas Resiko : B
Mar 10, 2023
DYMIND Hematology Calibrator
Kelas Resiko : B
Mar 8, 2023
DYMIND Hematology Control (Control Set)
Kelas Resiko : B
Mar 8, 2023
DYMIND Hematologi Analyzer Lyse LYC-1
Kelas Resiko : B
Mar 8, 2023
Recent Registrations (5 most recent)
Most recently registered products with BPOM
DYMIND Hematology Analyzer Lyse LYC-2
Class:
Kelas : 2
Risk Class:
Kelas Resiko : B
Registration Date:
Mar 10, 2023
DYMIND Hematology Analyzer Diluent DIL-C
Class:
Kelas : 2
Risk Class:
Kelas Resiko : B
Registration Date:
Mar 10, 2023
DYMIND Hematology Calibrator
Class:
Kelas : 2
Risk Class:
Kelas Resiko : B
Registration Date:
Mar 8, 2023
DYMIND Hematology Control (Control Set)
Class:
Kelas : 2
Risk Class:
Kelas Resiko : B
Registration Date:
Mar 8, 2023
DYMIND Hematologi Analyzer Lyse LYC-1
Class:
Kelas : 2
Risk Class:
Kelas Resiko : B
Registration Date:
Mar 8, 2023

